期刊
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
卷 50, 期 3, 页码 303-307出版社
ELSEVIER SCIENCE BV
DOI: 10.1016/j.ijantimicag.2017.05.006
关键词
Staphylococcus aureus; Tedizolid; Dalbavancin; Ceftaroline; Ceftobiprole; Oritavancin
A number of novel antimicrobial drugs with activity against Gram-positive bacterial pathogens have been licensed in the past 4 years. These drugs have the potential to enrich the group of intravenous drugs already available that are in common use againstmethicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant enterococci and other antibiotic-resistant Gram-positive pathogens. The advantages and disadvantages of these drugs are not yet fully appreciated. Here we review the five most promising newly approved compounds, namely ceftaroline, ceftobiprole, oritavancin, dalbavancin and tedizolid. The advantages of their dosing regimens, mechanisms of action and adverse effect profiles as well as evidence for their clinical usefulness and the unique characteristics that distinguish them from one another and from older drugs are reviewed. (C) 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据